Chordia Therapeutics Inc. (JP:190A) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chordia Therapeutics Inc. reported a challenging fiscal year ending August 2024, with net losses across the board and a basic earnings per share drop to -31.11 yen. The company’s total assets decreased from the previous year, while its equity ratio slightly fell from 91.2% to 89.8%. Despite negative cash flows from operating activities, Chordia Therapeutics maintains a positive cash and cash equivalents balance of 4,329 million yen.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.